Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
← catalyst calendarNCT06603558 · readout ≤ 1,016 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,000estimated
Sites
36
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-24 | actual | When the study began enrolling |
| Primary completion | May 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Migraine
- Episodic Migraine
- Migraine
Intervention
- Drug: Atogepant — also filed as Qulipta, Aquipta
Primary outcomes
what the primary-completion date above is the date OFPercentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported known (labeled) ADR
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported non-serious AE/ADR
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the Risk Management Plan (RMP)
measured Up to approximately 16 Weeks
Percentage (%) of participants with AE: overall summary
measured Up to approximately 16 Weeks
Percentage (%) of participants with common (>=5%) AE
measured Up to approximately 16 Weeks
Percentage (%) of participants with AE leading to treatment discontinuation
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment
measured Up to approximately 16 Weeks
Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment
measured Up to approximately 16 Weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed